Oximes as inhibitors of low density lipoprotein oxidation

Life Sciences

Volumn 83, Issue 25-26, 2008, Pages 878-885

  de Lima Portella, Rafael ^a   Barcelos, Rômulo Pillon ^a   de Bem, Andreza Fabro ^b   Carratu, Vanessa Santana ^c   Bresolin, Leandro ^d   da Rocha, João Batista Teixeira ^a   Soares, Félix Alexandre Antunes ^a  

^a FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^b FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE   (Brazil)

^d UNIVERSIDADE FEDERAL DO ACRE   (Brazil)

Author keywords

Atherosclerosis; Copper; Low density lipoprotein; Oxime; Serum

Indexed keywords

3 (PHENYLHYDRAZONO)BUTAN 2 ONE OXIME; APOLIPOPROTEIN B; BUTANE 2,3 DIONETHIOSEMICARBAZONE OXIME; CUPRIC ION; LOW DENSITY LIPOPROTEIN; OXIME DERIVATIVE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRYPTOPHAN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROGENESIS; DRUG MECHANISM; DRUG STRUCTURE; LIPID OXIDATION;

EID: 84984540740     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2008.10.005     Document Type: Article

References (68)

1. Alul R.H., Wood M., Longo J., Marcotte A.L., Campione A.L., Moore M.K., and Lynch S.M. Vitamin C protects low-density lipoprotein from homocysteine-mediated oxidation. Free Radical Biology and Medicine 34 (2003) 881-891
2. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., and Rosenblat M. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101 (2000) 2510-2517
3. Bem A.F., Farina M., Portella R.L., Nogueira C.W., Dinis T.C.P., Laranjinha J.A.N., Almeida L.M., and Rocha J.B. Diphenyl diselenide, a simple glutathione peroxidase mimetic, inhibits human LDL oxidation in vitro. Atherosclerosis 201 (2008) 92-100
4. Berrougui H., Cloutier M., Isabelle M., and Khalil A. Phenolic-extract from argan oil (Argania spinosa L.) inhibits human low-density lipoprotein (LDL) oxidation and enhances cholesterol efflux from human THP-1 macrophages. Atherosclerosis 184 (2006) 389-396
5. Carpenter K.L., Taylor S.E., van der Veen C., Williamson B.K., Ballantine J.A., and Mitchinson M.J. Lipids and oxidized lipids in human atherosclerotic lesions at different stages of development. Biochimica et Biophysica Acta 1256 (1995) 141-150
6. Cathcart M.K., Morel D.W., and Chisolm G.M. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. Journal of Leukocyte Biology 38 (1985) 341-350
7. Cynshi O., Kawabe Y., Suzuki T., Takashima Y., Kaise H., Nakamura M., Ohba Y., Kato Y., Tamura K., Hayasaka A., Higashida A., Sakaguchi H., Takeya M., Takahashi K., Inoue K., Noguchi N., Niki E., and Kodama T. Antiatherogenic effects of the antioxidant BO-653 in three different animal models. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 10123-10128
8. Dabbagh A., and Frei B. Human suction blister interstitial fluid prevents metal ion-dependent oxidation of low density lipoprotein by macrophages and in cell-free systems. The Journal of Clinical Investigation 96 (1995) 1958-1966
9. Daugherty A., Dunn J.L., Rateri D.L., and Heinecke J.W. Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. The Journal of Clinical Investigation 94 (1994) 437-444
10. De Rijke Y.B., Verwey H.F., Vogelezang C.J., Van Der Velde E.A., Princen H.M., Van Der Laarse A., Bruschke A.V., and Van Berkel T.J. Enhanced susceptibility of low density lipoproteins to oxidation in coronary bypass patients with progression of atherosclerosis. Clinica Chimica Acta; International Journal of Clinical Chemistry 243 (1995) 137-149
11. Durrington P.N., Mackness B., and Mackness M.I. Paraoxonase and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 21 (2001) 473-480
12. Esterbauer H. Cytotoxicity and genotoxicity of lipid-oxidation products. The American Journal of Clinical Nutrition 57 (1993) 779S-785S
13. Esterbauer H., Striegl G., Puhl H., and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radical Research Communications 6 (1989) 67-75
14. Esterbauer H., Gebicke J., Puhl H., and Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radical Biology and Medicine 13 (1992) 341-390
15. Frei B., and Gaziano J.M. Content of antioxidants, preformed lipid hydroperoxides, and cholesterol as predictors of the susceptibility of human low density lipoprotein to metalion dependent and -independent oxidation. Journal of Lipid Research 34 (1993) 2135-2145
16. Gieseg S.P., and Esterbauer H. Low density lipoprotein is saturable by pro-oxidant copper. FEBS Letters 343 (1994) 188-194
17. Giessauf A., Steiner E., and Esterbauer H. Early destruction of tryptophan residues of apolipoprotein B is a vitamin E-independent process during copper-mediated oxidation of LDL. Biochimica et Biophysica Acta 1256 (1995) 221-232
18. Girotti A.W. Lipid hydroperoxide generation, turnover, and effector action in biological systems. Journal of Lipid Research 39 (1998) 1529-1542
19. Gotoh N., Noguchi N., Suchiyaj T., Morita K., Sakai H., Shimasaki H., and Niki E. Inhibition of oxidation of LDL by vitamin E and related compounds. Free Radical Research 24 (1996) 123-134
20. Gray A.P. Design and structure-activity relationships of antidotes to organophosphorus anticholinesterase agents. Drug Metabolism Reviews 15 (1984) 557-589
21. Halliwell B. Oxygen radicals, nitric oxide and human inflammatory joint disease. Annals of the Rheumatic Diseases 54 (1995) 505-510
22. Hansson G.K. Immune mechanisms in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 21 (2001) 1876-1890
23. Hazell L.J., Arnold L., Flowers D., Waeg G., Malle E., and Stocker R. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. The Journal of Clinical Investigation 97 (1996) 1535-1544
24. Heinecke J.W., Baker H., Rosen H., and Chait A. Superoxide mediated modification of low density lipoprotein by human arterial smooth muscle cells. The Journal of Clinical Investigation 77 (1986) 757-762
25. Heinecke J.W., Kawamura M., Suzuki L., and Chait A. Oxidation of low density lipoprotein by thiols: superoxide dependent and independent mechanisms. Journal of Lipid Research 34 (1993) 2051-2061
26. Hiramatsu K., Rosen H., Heinecke J.W., Wolfbauer G., and Chait A. Superoxide initiates oxidation of low density lipoprotein by human monocytes. Arteriosclerosis 7 (1987) 55-60
27. Jialal I., and Devaraj S. Low-density lipoprotein oxidation, antioxidants, and atherosclerosis: a clinical biochemistry perspective. Clinical Chemistry 42 (1996) 498-506
28. Karten B., Beisiegel U., Gercken G., and Kontush A. Mechanisms of lipid peroxidation in human blood plasma: a kinetic approach. Chemistry and Physics of Lipids 88 (1997) 83-96
29. Kawamura M., Heinecke J.W., and Chait A. Pathophysiological concentrations of glucose promote oxidative modification of low density lipoprotein by a superoxide-dependent pathway. The Journal of Clinical Investigation 94 (1994) 771-778
30. Kawamura M., Heinecke J.W., and Chait A. Increased uptake of alpha-hydroxy aldehyde-modified low density lipoprotein by macrophage scavenger receptors. Journal of Lipid Research 41 (2000) 1054-1059
31. Kontush A., Hubner C., Finckh B., Kohlshutter A., and Beisiegel U. Low density lipoprotein oxidizability by copper correlates to its initial ubiquinol 10 and polyunsaturated fatty acid content. FEBS Letters 341 (1994) 69-73
32. Lapenna D., de Gioia S., Ciofani G., Bruno C., Porreca E., Pierdomenico S.D., and Cuccurullo F. Antioxidant properties of ticlopidine on human low density lipoprotein oxidation. FEBS Letters 436 (1998) 357-360
33. Lass A., Witting P., Stocker R., and Esterbauer H. Inhibition of copper- and peroxyl radical-induced LDL lipid oxidation by ebselen: antioxidant actions in addition to hydroperoxide-reducing activity. Biochimica et Biophysica Acta 1303 (1996) 111-118
34. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
35. Lópes-Alarcón C., Speisky H., and Lissi E. Antioxidant effect of 5-amino salicylic acidon copper-mediated LDL oxidation. Biological Research 40 (2007) 155-162
36. Lowry O.H., Rosenbrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin-phenol reagent. The Journal of Biological Chemistry 193 (1951) 265-275
37. Mackness M., Durrington P., and Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease. Current Opinion in Lipidology 15 (2004) 399-404
38. Maggi E., Belazzi R., Falaschi F., Frattoni A., Perani G., Finardi G., Gazo A., Nai M., Romanini D., and Bellomo G. Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis?. Kidney International 45 (1994) 876-883
39. Menache R., Kenda L., Shaked P., Schwartzman S., and Lewinski U. The prognostic value of serum acetylcholinesterase in myocardial infarction. Theoretical and clinical considerations. Research in Experimental Medicine (Berl.) 181 (1982) 181-187
40. Nandi A.K., Chaudhuri S., and Mazumdar S.K. Structure of 3-hydroxyimino-2-butanone thiosemicarbazone, a tridentate N-S ligand, C5H10N4OS. Acta Crystallographica C 40 (1984) 1193-1196
41. O'Leary V.J., Darley-Usmar V.M., Russell L.J., and Stone D. Pro-oxidant effects of lipoxygenase-derived peroxides on the copper-initiated oxidation of low density lipoprotein. The Biochemical Journal 282 (1992) 631-634
42. Ohkawa H., Ohishi H., and Yagi K. Assay for lipid peroxide in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry 95 (1979) 351-358
43. Parthasarathy S., Printz D.J., Boyd D., Joy L., and Steinberg D. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis 6 (1986) 505-510
44. Parthasarathy S., Quinn M.T., Schwenke D.C., Carew T.E., and Steinberg D. Oxidative modification of beta-very low density lipoprotein. Potential role in monocyte recruitment and foam cell formation. Arteriosclerosis 9 (1989) 398-404
45. Proudfoot J.M., Puddey I.B., Beilin L.J., Stocker R., and Croft K.D. Unexpected dose response of copper concentration on lipoprotein oxidation in serum: discovery of a unique peroxidase-like activity of urate/albumin in the presence of high copper concentrations. Free Radical Biology and Medicine 23 (1997) 699-705
46. Puntel G.O., Gubert P., Peres G.L., Bresolin L., Rocha J.B.T., Pereira M.E., and Carratu V.S. Antioxidant properties of oxime 3-(phenylhydrazono) butan-2-one. Archives of Toxicology 82 (2008) 755-762
47. Reaven P., Parthasarathy S., Grasse B.J., Miller E., Alonazan F., Mattson F.H., Khoo J.C., Steinberg D., and Witztum J.L. Feasibility of using an oleate rich diet to reduce the susceptibility of LDL to oxidative modification in humans. The American Journal of Clinical Nutrition 54 (1991) 701-706
48. Refsgaard H.H.F., Tsai L., and Stadtman E.R. Modifications of proteins by polyunsaturated fatty acid peroxidation products. Proceedings of the National Academy of Sciences of the United States of America 97 (2000) 611-616
49. Regnström J., Nilsson J., Tornvall P., Landau C., and Hamsten A. Susceptibility to low-density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339 (1992) 1183-1186
50. Reyftmann J.P., Santus R., Mazière J.C., Morlière J.C., Salmon S., Candide C., Mazière C., and Haigle J. Sensitivity of tryptophane and related compounds to oxidation induced by lipid autoperoxidation. Application to human low- and high-density lipoproteins. Biochimica et Biophysica Acta 1042 (1990) 159-167
51. Rice-Evans C., Leake D., Bruckdorfer R., and Diplock A.T. Practical approaches to low density lipoprotein oxidation: whys, wherefores and pitfalls. Free Radical Research 25 (1996) 285-311
52. Schnitzer E., Pinchuk I., Bor A., Fainaru M., Samuni A.M., and Lichtenberg D. Lipid oxidation in unfractionated serum and plasma. Chemistry and Physics of Lipids 92 (1998) 151-170
53. Schwartz C.J., Valente A.J., Sprague E.A., Kelley J.L., and Nerem R.M. The pathogenesis of atherosclerosis: an overview. Clinical Cardiology 14 (1991) I1-I16
54. Silva A.P., Farina M., Franco J.L., Dafre A.L., Kassa J., and Kuca K. Temporal effects of newly developed oximes (K027, K048) on malathion-induced acetylcholinesterase inhibition and lipid peroxidation in mouse prefrontal cortex. Neurotoxicology 29 (2008) 184-189
55. Silva E.L., Tsushida T., and Terao J. Inhibition of mammalian 15-lipoxygenase-dependent LDL lipid peroxidation by quercetin and quercetinmonoglucosides. Archives of Biochemistry and Biophysics 349 (1998) 313-320
56. Spranger T., Finckh B., Fingerhut R., Kohlschütter A., Beisiegel U., and Kontush A. How different constituents of human plasma and low density lipoprotein determine plasma oxidizability by copper. Chemistry and Physics of Lipids 91 (1998) 39-52
57. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. The New England Journal of Medicine 320 (1989) 915-924
58. Steinbrecher U.P., Parthasarathy S., Lee D.C., Witztum J.L., and Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proceedings of the National Academy of Sciences of the United States of America 81 (1984) 3883-3887
59. Suarna C., Dean R.T., May J., and Stocker R. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of α-tocopherol and ascorbate. Arteriosclerosis, Thrombosis, and Vascular Biology 15 (1995) 1616-1624
60. Swain J., and Gutteridge J.M. Prooxidant iron and copper, with ferroxidase and xanthine oxidase activities in human atherosclerotic material. FEBS Letters 368 (1995) 513-515
61. Tangirala R.K., Casanada F., Miller E., Witztum J.L., Steinberg D., and Palinski W. Effect of the antioxidant N,N′-diphenyl 1,4-phenylenediamine (DPPD) on atherosclerosis in ApoE-deficient mice. Journal of Lipid Research 15 (1995) 1625-1630
62. Thomas J.P., Kalyanaraman B., and Girotti A.W. Involvement of preexisting lipid hydroperoxides in copper stimulated oxidation of low density lipoprotein. Archives of Biochemistry and Biophysics 315 (1994) 244-254
63. Walzem R.L., Watkins S., Frankel E.N., Hansen R.J., and German J.B. Older plasma lipoproteins are more susceptible to oxidation: linking mechanism for the lipid and oxidation theories of atherosclerotic cardiovascular disease. Proceedings of the National Academy of Sciences of the United States of America 92 (1995) 7460-7464
64. Witting P.K., Pettersson K., Ostlund-Lindqvist A.M., Westerlund C., Eriksson A.W., and Stocker R. Inhibition by a coantioxidant of aortic lipoprotein lipid peroxidation and atherosclerosis in apolipoprotein E and low-density lipoprotein receptor gene double knockout mice. The FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 13 (1999) 667-675
65. Witztum J.L., and Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. The Journal of Clinical Investigation 88 (1991) 1785-1792
66. Witzum J.L. The oxidation hypothesis of atherosclerosis. Lancet 344 (1994) 793-795
67. Ylä-Herttuala S., Palinski W., Rosenfeld M.E., Parthasarathy S., Carew T.E., Butler S., Witztum J.L., and Steinberbet D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. The Journal of Clinical Investigation 84 (1989) 1086-1095
68. Ziouzenkova O., Sevanian A., Abuja P.M., Ramos P., and Esterbauer H. Copper can promote oxidation of LDL by markedly different mechanisms. Free Radical Biology and Medicine 24 (1998) 607-623